BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GALNS: Preliminary Extension study data

Preliminary data from the ongoing MOR-100 extension of the open-label, dose-escalation Phase I/II MOR-002 trial in about 15 patients showed that weekly IV GALNS for an additional 24 weeks led to further improvements in mean 6MWT distance, 3-minute stair climb rate and FVC from baseline. Patients had already received weekly...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >